Arsenal Capital Partners Appoints Spaight As Operating Partner

Oct 17 2016 | 7:07pm ET

Close on the heels of raising $1.3 billion for its latest private equity fund, Arsenal Capital Partners has brought former WIL Research Company CEO David Spaight aboard as an operating partner within the firm’s healthcare group.

Spaight led the successful turnaround of WIL Research, a global contract research organization focused on preclinical R&D and contract development and manufacturing services, and led the firm’s $585 million sale to Charles River Laboratories earlier this year. Prior to joining WIL Research in 2010, Spaight held senior executive positions at leading biopharma services and life sciences companies including MDS Pharma Services, ThermoFisher and PerkinElmer. 

“David’s career has been characterized by 30 years of innovative executive leadership experience in biopharma services and life sciences,” said Dr. Donald Deieso, Arsenal operating partner and co-head of Arsenal’s healthcare group, in a statement. “We are delighted to have him bring his unique set of skills to help guide the growth and impact of our portfolio companies.”

Founded in 2000 and based in New York, Arsenal Capital Partners invests in lower middle-market specialty industrial and healthcare companies. Since inception, Arsenal has raised institutional equity investment funds totaling $2.975 billion, has made 34 platform investments and completed 21 realizations since inception.

In Depth

Q&A: Portfolio Advisors' Brian Murphy On The Advantages of A Private Markets Platform

Jan 2 2018 | 11:05am ET

Most private markets firms reference their platforms as a source of competitive...


CFA Institute To Add Computer Science To Exam Curriculum

May 24 2017 | 9:25pm ET

Starting in 2019, financial industry executives sitting for the coveted Chartered...

Guest Contributor

Steinbrugge: The Top Hedge Fund Industry Trends for 2018

Jan 2 2018 | 12:22pm ET

Each year, Don Steinbrugge’s Agecroft Partners compiles the insights gained...